A combination of increased meningococcal carriage and common social behaviours put adolescents and young adults at increased risk of infection.
N. Meningitidis carriage is often asymptomatic but can lead to IMD. Meningococcal bacteria carriage increases during late adolescence to a peak of approximately 24% in 19 year olds. The typical behaviours and lifestyles of people in this age bracket are compatible with transmission meningococcal bacteria.
Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by N. Meningitidis serogroup B.
Trumenba requires 2 doses 6 months apart at £145 per dose.
To book an appointment contact us on 01883 212010 or email: email@example.com